News

Food for Thought: What Would You Do With a Personal Sequencer?

Basically, it is the smallest pH meter in the world, but its impact on science, medicine, and even daily life is likely to be huge. The pH meter developed by Ion Torrent sits on a semiconductor chip beneath very tiny wells containing a single-stranded DNA probe and DNA polymerase in a buffer. The wells are flooded by the nucleotides A, T, G and C in a sequential manner, and incorporation is recorded by measuring the proton released in the reaction. Thereby, the pH meter can be used to sequence DNA. The chip contains 1.3 million wells, the device measures about 60x50x55 cm (24x20x21 inches), costs $50,000 and is named  PGM – Personal Genome Machine.

Already on the market, it puts DNA sequencing within the reach of nearly every lab, doctor’s practice, clinic, and even college. While it still has certain limitations – it can read only 20 genes at once at present – DNA sequencing never has been easier and less error-prone. Other devices with similar elegance and even more speed are around the corner – as an example, scientists from Imperial College of London last month demonstrated in NanoLetters that they can sequence genes by propelling a DNA strand at high speed through a tiny 50 nanometre (nm) hole cut in a silicon chip, using an electrical charge. As the strand emerges from the nanopore, its coding sequence is read by a ‘tunnelling electrode junction’. This 2 nm gap between two wires supports an electrical current that interacts with the distinct electrical signal from each base code. The speed is unbelievable and translates into sequencing an entire human genome in 5 minutes.

Certainly, these machines will have a huge impact on the amount of data generated for the development of personalized medicine and individualized therapies. But now that DNA sequencing is approaching a mass market, it will inevitably reach anyone, just like cameras, computers and mobile phones that turned from “professional only” machines into commodities. The statement that no one needs such a machine is refuted by history: when the telephone was invented, US president Rutherford B. Hayes could not think of anyone wanting to use it, XEROX once was sure that the world market for photocopiers would be around 50 machines, and even Intel’s founder Gordon Moore could not think of using personal computers at home for anything meaningful other than “maybe filing cooking recipes”.

What would you do with a personal sequencer at home? Screen your blood for disease on a daily basis? Check your food for microbial contamination? Classify the bugs and shrubs in your garden to find new ones? Secretly sequence the DNA of you neighbors, boss or affair to find out about genetic weaknesses? In a decade, ads might state once again: “There is an APP for that!”

Company News: biocrea expands management team

The German biotech company biocrea GmbH today announced the expansion of its management team by appointing Martin Gunthorpe (formerly GlaxoSmithKline, GSK) as Chief Scientific Officer, Viktor Viehweg (formerly Sibur Ltd.) to the position of Chief Financial Officer, and Simon Ward (formerly GSK) to Executive Vice President Chemistry & Development.

biocrea was established in November 2010 following a management buy-out from Biotie Therapies Corp. (HSE: BTH1V; Turku, Finland). In the transaction, biocrea acquired the CNS pipeline and a cyclic nucleotide phosphodiesterase (PDE) inhibitor platform from Biotie. biocrea’s team has a long-standing, exceptional track record in the development of CNS therapeutics, e.g. the development of a PDE10 inhibitor portfolio for the treatment of schizophrenia in collaboration with Wyeth Pharmaceuticals and Pfizer, which acquired Wyeth in 2009. The company plans to expand its pipeline and to obtain attractive assets in order to build a more mature portfolio. Already, it is in advanced negotiations with several pharma partners, such as GSK.

biocrea’s management will attend the J.P. Morgan 29th Annual Healthcare Conference 2011, San Francisco, January 10-13, 2011. If you wish to make an appointment, please contact akampion via info@akampion.com.

Food for Thought: Update on Germany´s Drug Reimbursement Law

Based on the latest developments in the debate about Germany´s new drug reimbursement law (AMNOG), we have updated our analysis, which was originally published in September 2010.  Please click here for the updated article.

Company News: SuppreMol closes C round, receives grant

Munich-based biotech company SuppreMol this month announced the closing of a EUR15.5 M C round as well as receiving a EUR1.6 M public research grant.

The money will be used for the GMP production and further clinical studies of its lead candidate SM101, a recombinant, soluble, non-glycosylated version of the Fc gamma receptor IIb. SM101, which has been granted orphan drug designation in the European Union and in the US, has already entered Phase Ib/IIa clinical studies in Primary Immune Thrombocytopenia (ITP), with interim results anticipated for next year. In addition, the company plans to initiate a Phase IIa study in Systemic Lupus Erythematosus (SLE) mid next year.

Moreover, SuppreMol will explore the therapeutic potential of  SM101 in Lupus Nephritis, a subcategory of this autoimmune disease affecting primarily the kidneys, and evaluate the compound in animal models for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Last not least, the funds will be used for the preclinical development of an anti-FcgRIIb monoclonal antibody, which, due to the different properties of this molecule compared to SM101, may have beneficial therapeutic potential in certain autoimmune diseases.

The C round was led by MIG AG with BioMedPartners AG  as co-lead. The other existing investors Santo Holding GmbH, KfW Mittelstandsbank, Bayern Kapital GmbH and Max-Planck-Gesellschaft also participated in the round which was joined by FCP Biotech Holding GmbH as new investor.

1 186 187 188 200